Navigation Links
New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyl's HNO Donors As Novel Treatments For Heart Failure
Date:10/28/2013

CHAPEL HILL, N.C., Oct. 28, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the publication of recent findings on the role of a novel pure nitroxyl (HNO) donor in enhancing cardiac function and hemodynamics. These findings, based upon analysis of preclinical and human clinical data from studies of CXL-1020, were published online October 9, 2013, in Circulation: Heart Failure, which is published by the American Heart Association.

"Patients with acute decompensated heart failure (ADHF) present with a complex and often life-threatening clinical syndrome – and new therapeutic advances remain scant. These published data demonstrate the functional improvement in myocardial performance produced by a novel pure HNO donor, and show first-in-human evidence for the potential utility of an HNO donor in heart failure," said Wilson "Bill" S. Colucci, M.D., Thomas J. Ryan Professor of Medicine and Chief of the Cardiovascular Medicine Section at Boston University Medical Center, who served as Chairman of the Steering Committee for the CXL-1020 Phase 2a clinical study.

The data published in Circulation: Heart Failure summarize study findings from two preclinical models as well as a clinical study examining the hemodynamic effects and safety of CXL-1020 at doses of 1–20 mg/kg/min in patients with advanced heart failure hospitalized for invasive hemodynamic monitoring. Investigators reported human data demonstrating that CXL-1020, a novel pure HNO donor, enhanced cardiac systolic function while reducing pulmonary capillary wedge pressure (PCWP) and arterial and venous tone without increasing heart rate. Consistent with the clinical data, direct contractile enhancement from CXL-1020 was observed in isolated myocytes as well as in vivo in experimental canine heart failure models. The investigators concluded that the combination of effects differentiates HNO donors from other classes of inotropes or ino-dilators, and provides a strong rationale for continuing studies to develop donors with optimized pharmacology for the treatment of congestive heart failure.

"Cardioxyl is excited about these results obtained with our first-generation HNO donor, and is poised to expand upon this data as we prepare to bring our second-generation HNO donor into the clinic next year," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer.

The study is available online, via subscription, at http://circheartfailure.ahajournals.org/content/early/2013/10/09/CIRCHEARTFAILURE.113.000632

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARUP Laboratories Presents Recent Findings at PAINWeek
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
4. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
5. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
6. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
8. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
9. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
10. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
11. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):